PLASMA NATRIURETIC PEPTIDES LEVELS AND ECHOCARDIOGRAPHIC FINDINGS IN LATE SUBCLINICAL ANTHRACYCLINE TOXICITY

REFERENCES

• Steinherz LJ, Steinherz PG, Tan CTC. Cardiac failure and dysrhytmias 6–19 years after anthracycline therapy: A series of 15 patients. Med Pediatr Oncol. 1995; 24: 352–361
   PubMedGoogle Scholar
• Goorin AM, Chauvenet AR, Perez-Atayde AR. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990; 116: 144–147
   PubMed Web of Science ®Google Scholar
• Yeung ST, Yoong C, Spink J. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet. 1991; 337: 816–816
   PubMed Web of Science ®Google Scholar
• Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institute Goustave Roussy. Br J Cancer 2004; 91: 37–44
   PubMed Web of Science ®Google Scholar
• Prestor VV, Rakovec P, Kozelj M, et al. Late cardiac damage of anthracycline therapy for acute lymphoblastic leukemia in childhood. Pediatr Hematol Oncol. 2000; 17: 527–540
   PubMed Web of Science ®Google Scholar
• Rathe M, Carlsen NLT, Oxhoj H. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 48: 663–667
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991; 324: 808–815
   PubMed Web of Science ®Google Scholar
• Pautanen T, Tikanoja T, Riikonen P, et al. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol. 2003; 21: 2349–2356
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23: 2629–2636
   PubMed Web of Science ®Google Scholar
• Nousiainen T, Jantunen E, Vanninen E, et al. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol. 1999; 62: 135–141
   PubMed Web of Science ®Google Scholar
• Tikanoja T, Riikonen P, Perkkio M, et al. Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up children with cancer. Med Pediatr Oncol. 1998; 31: 73–78
   PubMedGoogle Scholar
• Hayakawa H, Komada Y, Hirayama M, et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 2001; 37: 4–9
   PubMedGoogle Scholar
• Solymar L, Marky I, Mellander L. Echocardiographic findings in children treated for malignancy with chemotherapy including adriamycin. Pediatr Hematol Oncol. 1988; 5: 209–216
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Rifai N, Sallan SE. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96: 2641–2648
   PubMed Web of Science ®Google Scholar
• Wassmuth R, Lentzsch S, Erdbruegger U, et al. Subclinical cardiotoxic effets of anthracyclines as assessed by magnetic resonance imaging: A pilot study. Am Heart J. 2001; 141: 1007–1013
   PubMed Web of Science ®Google Scholar
• Agarwala S, Kumar R, Bhatnagar V, et al. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography. J Pediatr Surg. 2000; 35: 1786–1789
   PubMed Web of Science ®Google Scholar
• Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996; 14: 362–372
   PubMed Web of Science ®Google Scholar
• Bossi G, Lanzarini L, Laudisa ML, et al. Echocardiographic evaluation of patients cured of childhood cancer: A single center study of 117 subjects who received anthracyclines. Med Pediatr Oncol. 2001; 36: 593–600
   PubMedGoogle Scholar
• Lenk MK, Zeybek C, Okutan V, et al. Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography. Turk J Pediatr. 1998; 40: 373–383
   PubMed Web of Science ®Google Scholar
• Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997; 350: 1347–1352
   Web of Science ®Google Scholar
• Kakedekar AP, Sandor GG, Fryer C, et al. Differences in dose scheduling as a factor in the etiology of anthracycline-induced cardiotoxicity in Ewing sarcoma patients. Med Pediatr Oncol. 1997; 28: 22–26
   PubMedGoogle Scholar
• Turner-Gomes SO, Lands LC, Haklton J, et al. Cardiorespiratory status after treatment for acute lymphoblastic leukemia. Med Pediatr Oncol. 1996; 26: 160–165
   PubMedGoogle Scholar
• Iarussi D, Galderisi M, Ratti G, et al. Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood. Clin Cardiol. 2001; 24: 663–669
   PubMed Web of Science ®Google Scholar
• Hudson MM, Rai SN, Nunez C, et al. Noninvasive evaluation of late anthracycline cardic toxicity in childhood cancer survivors. J Clin Oncol. 2008; 25: 3635–3643
   Web of Science ®Google Scholar
• Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J Clin Invest. 1991; 87: 1402–1412
   PubMed Web of Science ®Google Scholar
• Fossmann WG, Richter R, Meyer M. The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. Histochem Cell Biol. 1998; 110: 335–357
   PubMed Web of Science ®Google Scholar
• Germanakis I, Kalmanti M, Parthenakis F, et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol. 2006; 108: 212–215
   PubMed Web of Science ®Google Scholar
• Pinarli FG, Oguz A, Tunaoglu FS, et al. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer. 2005; 44: 370–377
   PubMed Web of Science ®Google Scholar
• Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2004; 118–145
   PubMedGoogle Scholar
• Sahn Dj, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation M-mode echocardiography: results of a survey of echocardiograhic measurements. Circulation. 1978; 58: 1072–1078
   PubMed Web of Science ®Google Scholar
• Mercier JC, Disesa TG, Jarmakani JM, et al. Two-dimensional echocardiographic assessment of left ventricular volumes and ejection fraction in children. Circulation. 1982; 65: 962–969
   PubMed Web of Science ®Google Scholar
• Colan SD, Borow KM, Neuman A. Left ventricular end-systolic wall stress velocity of fiber shortening relation: a load independent index of myocardial contractility. J Am Coll Cardiol. 1984; 4: 715–724
   PubMed Web of Science ®Google Scholar
• Rowland DG, Gutgesell HP. Use of mean arterial pressure for non-invasive determination of left ventricular end systolic wall stress in infants and children. Am J Cardiol. 1994; 74: 98–99
   PubMed Web of Science ®Google Scholar
• Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57: 450–458
   PubMed Web of Science ®Google Scholar
• Tei C. New noninvasive index for combined systolic and diastolic ventricular function. J Cardiol. 1995; 26: 135–136
   PubMedGoogle Scholar
• Eidem BW, Sapp BG, Suarez CR, et al. Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol. 2001; 87: 1120–1122
   PubMed Web of Science ®Google Scholar
• Langer T, Stöhr W, Bielack S, et al. Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer. 2004; 42: 373–379
   PubMed Web of Science ®Google Scholar
• Postma A, Bink-Boelkens MT, Beaufort-Krol GC, et al. Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol 1996; 26: 230–237
   PubMedGoogle Scholar
• Rammeloo LAJ, Postma A, Sobotka-Plojhar MA, et al. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Group. Med Pediatr Oncol. 2000; 35: 13–19
   PubMedGoogle Scholar
• Creutzig U, Diekamp S, Zimmermann M, Reinhardt D. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer 2007; 48: 651–662
   PubMed Web of Science ®Google Scholar
• Nousiainen T, Jantunen E, Vanninen E, et al. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur J Haematol. 1998; 61: 347–353
   PubMed Web of Science ®Google Scholar
• Okumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol. 2000; 104: 158–163
   PubMed Web of Science ®Google Scholar